Article Text

Download PDFPDF

AB0364 Remarkable international variability in reasons for non-participation in the gloria trial
  1. L. Hartman1,
  2. R. Bos2,
  3. F. Buttgereit3,
  4. M. Güler-Yuksel4,
  5. R. Ionescu5,
  6. M. Kok4,
  7. W. Lems1,
  8. M. Micaelo6,
  9. D. Opris-Belinski5,
  10. A. Pusztai7,
  11. E. Santos8,
  12. J. da Silva8,
  13. Z. Szekanecz7,
  14. K. Zeiner3,
  15. D. Zhang2,
  16. M. Boers1,9
  1. 1Amsterdam Rheumatology and Immunology Center ARC, Amsterdam
  2. 2Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands
  3. 3Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany
  4. 4Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands
  5. 5Department of Internal Medicine and Rheumatology, ‘’Sf. Maria’’ Hospital, University of Medicine and Pharmacy ‘’Carol Davila’’, Bucharest, Romania
  6. 6Instituto Português de Reumatologia, Lisbon, Portugal
  7. 7Department of Rheumatology, University of Debrecen Faculty of Medicine, Debrecen, Hungary
  8. 8Reumatologia, Faculdade de Medicina e Hospitais da Universidade de Coimbra, Coimbra, Portugal
  9. 9Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands

Abstract

Background GLORIA is an ongoing large pragmatic trial that examines harm, benefit and costs of low-dose glucocorticoids added to the standard treatment of RA patients of 65 years or older. The eligibility criteria are non-restrictive: RA, age ≥65 years, disease activity score (DAS28) of ≥2.6, and no current glucocorticoid treatment. Patients with comorbidity are expressly included, and the impact of trial procedures on normal care is minimal. Nevertheless, inclusion proves to be challenging. We have prospectively sampled all the reasons for ineligibility across a number of centres in different countries participating in the GLORIA trial.

Methods Rheumatologists from 8 centres in Germany, Hungary, The Netherlands, Portugal and Romania screened the patient list of at least two full clinic days. For each patient, the eligibility and all possible reasons of exclusion were recorded.

Abstract AB0364 – Table 1

Percentage of patients ineligible for the GLORIA trial, per reason (patients can have more than one reason)

Results In total, 385 patients were screened. Of these patients, 15 (4%) were eligible to participate in the GLORIA trial. In Germany, Romania and Portugal (Lisbon) none of the screened patients proved eligible.

The most common reasons for ineligibility were inactive disease and age (both 58%) (table 1). Current glucocorticoid use was reported in 28%, 5% had a temporary reason (i.e. recent switch of therapy or glucocorticoid use), and 51% had more than one reason for ineligibility. We found remarkable differences between the sites in the distribution of the main reasons for ineligibility (table 1).

Of the eligible patients, 1 was already participating, 3 were included after this screening, and 2 were currently considering participation; 9 declined participation (most common reasons: fear of glucocorticoids, not interested to participate, preference for GC injections or declining additional therapy).

Conclusions In this prospective study, we found remarkable differences between countries in reasons for non-participation in our ongoing GLORIA trial. The willingness of eligible patients to participate was low in this elderly population, despite the pragmatic design. Earlier studies also showed that it is challenging to include elderly patients in a clinical trial.1 2 Pre-screening of patients in potential sites can provide important information on the potential to recruit patients in a trial, but the actual willingness of patients to participate remains hard to predict.

References [1] Calamia M, et al. I’d Do Anything for Research, But I Won’t Do That: Interest in Pharmacological Interventions in Older Adults Enrolled in a Longitudinal Aging Study. PLoS One2016;11:e0159664.

[2] Denson AC, et al. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control2014;21:209–14.

Acknowledgements This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 6 34 886.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.